Key result
Anti-arrhythmic drug therapy during pregnancy requires careful individual risk-benefit assessment due to potential teratogenic effects and altered maternal pharmacokinetics.
Anti-arrhythmic drug therapy during pregnancy requires careful individual risk-benefit assessment due to potential fetal toxicity and altered maternal pharmacokinetics, and is primarily indicated for hemodynamic instability.
Answers are grounded in this paper and cite their sources.
Supports individualized AAD decisions in pregnancy; leaves open need for prospective safety data.
Tachyarrhythmias are the most frequently observed cardiac complications during pregnancy. The majority of these maternal and foetal arrhythmias are supraventricular tachyarrhythmias; ventricular tachyarrhythmias are rare. The use of anti-arrhythmic drugs (AADs) during pregnancy is challenging due to potential foetal teratogenic effects. Maintaining stable and effective therapeutic maternal drug levels is difficult due to haemodynamic and metabolic alterations. Pharmacological treatment of tachyarrhythmias is indicated in case of maternal haemodynamic instability or hydrops fetalis. Evidenc e regarding the efficacy and safety of AAD therapy during pregnancy is scarce and the choice of AAD should be based on individual risk assessments for both mother and foetus. This review outlines the current knowledge on the development of tachyarrhythmias during pregnancy, the indications for and considerations of pharmacological treatment and its potential side-effects.
No takes yet. Share an insight, caveat, or question.
Yaksh et al. (2016) conducted a review in Tachyarrhythmias during pregnancy. Anti-arrhythmic drugs was evaluated. Anti-arrhythmic drug therapy during pregnancy requires careful individual risk-benefit assessment due to potential teratogenic effects and altered maternal pharmacokinetics.
Synapse has enriched 10 related papers. Consider them for comparative context: